Kwality Pharmaceuticals logo

Kwality Pharmaceuticals financials: balance sheet, profit and loss, cash flow

NSE: KPLBSE: 539997Pharmaceuticals & BiotechnologySmall Cap

Kwality Pharmaceuticals Limited · Face value ₹10 · Listed Jul 2016
Last close ₹3,696.70up ₹97.30 (2.70%)BSE ₹3,689.25

Share price at the NSE close on 28 Oct 2026. Previous close ₹3,599.40.

28 Oct: open ₹3,599.40, high ₹3,710.00, low ₹3,554.90

52-week range of BSE trades to 28 Oct 2026
₹828.80Low, 11 Nov 2025₹3,866.55High, 21 Sep 2026
Market cap
₹3,836 Cr1,235th largest listed
P/E
47.33
P/B
11.57
Dividend yield
Nonein the last 12 months
ROE
27.2%
ROCE
25.0%
Debt to equity
0.40
Volume, NSE
36,441

Kwality Pharmaceuticals' financial statements for the 10 years to Mar 2026, standalone: the listed company alone, without its subsidiaries, with the twelve months to Jun 2026 after them.

10 years at a glance

₹ crore, years to March.Kwality Pharmaceuticals annual reports

Revenue, net profit and borrowings, ₹ crore

  • Revenue
  • Net profit
  • Borrowings
953.4Mar 171374.7Mar 181657.526Mar 191398.431Mar 202621535Mar 2145612043Mar 222511990Mar 233072498Mar 2437040112Mar 2550367130Mar 26
Peak revenue ₹503 Cr, year to Mar 2026; lowest ₹95 Cr, year to Mar 2017

Operating and net margin, per cent

  • Operating margin
  • Net margin
37.6%3.4%9.0%8.4%37.6%24.0%21.7%21.7%23.5%3.6%3.4%4.6%6.1%5.9%26.3%7.8%7.8%10.8%13.4%Mar 17Mar 19Mar 21Mar 23Mar 25Mar 26

Results for the year to Mar 2026

Standalone: the listed company alone, without its subsidiaries. ₹ crore.

From revenue to net profit

  1. Revenue503
  2. Materials and goods−258
  3. Employee costs−54
  4. Other expenses−72
  5. Operating profit118
  6. Depreciation−20
  7. Other income+2.9
  8. One-off items−0.8
  9. Finance costs−11
  10. Profit before tax89
  11. Tax−22
  12. Net profit67

What the company owns

  • Receivables₹281 Cr
  • Plant, investments and other assets₹233 Cr
  • Inventory₹78 Cr
  • Cash and bank₹4 Cr

What pays for it: net worth and liabilities

  • Net worth₹333 Cr
  • Borrowings₹130 Cr
  • Owed to suppliers₹102 Cr
  • Other liabilities₹30 Cr

Profit and loss

Standalone, ₹ crore, years to March. The last column is the twelve months to Jun 2026, the latest four quarters added.Kwality Pharmaceuticals quarterly results

₹ croreMar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026Filed 19 MayJun 2026Twelve monthsFiled 10 Aug
Revenue from operations95137165139262456251307370503554
87125–––284191241290385419
Materials and goods bought7010111987166201110153182258288
Employee costs46–––203033445457
Other expenses1319–––645155647274
Operating profit before depreciation911–––172606780118135
Operating margin9.0%8.4%–––37.6%24.0%21.7%21.7%23.5%24.4%
Materials, % of revenue73.1%74.0%–––44.0%43.9%49.9%49.3%51.4%52.0%
Employee costs, % of revenue4.4%4.0%–––4.4%11.9%10.6%11.8%10.7%10.2%
Other expenses, % of revenue13.6%13.5%–––14.0%20.2%17.8%17.2%14.4%13.4%
Depreciation and amortisation23–––111520182020
Operating profit after depreciation69–––16145476298115
Other income21142432233
Finance costs222233610101111
Profit before one-off items and tax6811112216242395490107
One-off items––––––−17−70−1−1
Profit before tax6811112216226315489106
233364267142225
Net profit3588151201924406781
Other comprehensive income––––––00000
Total comprehensive income––––––1924406781
Net margin3.6%3.4%4.6%6.1%5.9%26.3%7.8%7.8%10.8%13.4%14.6%
Operating expenses, operating profit before depreciation and operating profit after depreciation are left blank for the years to Mar 2019, Mar 2020 and Mar 2021: the statement does not state its depreciation, which operating profit is worked out from, so operating profit is not given.

Balance sheet

Standalone, ₹ crore, at 31 March.

₹ croreMar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026Filed 19 May
394763183202226266333
Share capital1010101010101010
Reserves283752172192216255323
263135439098112130
616878130126152170226
820283029201537
Total assets107135169343357398451596
334663115149154166189
7489106227208243285407
Net debt22272532849398127
Borrowings are counted again inside the liabilities due within a year and after a year. No balance sheet is on record for the years to Mar 2017 and Mar 2018, so its lines and the ratios worked from it are blank there.

Cash flow

Standalone, ₹ crore, years to March.

₹ croreMar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026Filed 19 May
266342435317
3310448456938
2−712−23−14−83
Receivables−7−33−3−43−40−125
Inventories5−36−333−55
Payables38191146
Other working capital1−1037720−9
Tax paid−6−41−6−1−16−21
Capital spending235548302345
Free cash flow38−51430−28
−23−63−48−26−28−35
161−17−147
Dividends paid000000
Shares bought back––0000
Shares issued000000
Net change in cash46−5010−11
Capital spending is part of cash from investing, and dividends paid, shares bought back and shares issued are part of cash from financing. Each is shown as an amount on a line of its own, and the section's other items are in its total only. No cash flow statement is on record for the years to Mar 2017, Mar 2018, Mar 2019 and Mar 2020.

Per share

Standalone, ₹ per share, years to March.Kwality Pharmaceuticals dividend history

₹ per shareMar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026Filed 19 May
₹3.35₹4.51₹7.27₹8.13₹14.86₹115.70₹18.45₹23.11₹38.44₹64.90
As stated that year₹6.70₹4.51₹7.27₹8.13₹14.86₹115.70₹18.45₹23.11₹38.44₹64.90
₹3.35₹4.51₹7.27₹8.13₹14.86₹115.70₹18.45₹23.11₹38.44₹64.90
₹0.30–––––––––
Book value per share––₹37.26₹45.39₹60.24₹175.94₹194.70₹217.75₹256.21₹321.29
Dividend payout9.1%–––––––––
Shareholder yield––––0.0%0.0%0.0%0.0%0.0%0.0%
Market cap at the year end (₹ crore)50433827586023194259021,355
Every year is restated for later splits and bonuses, so they do not break the line. The figure the company stated that year is under each line it differs from.

Ratios

Standalone, years to March.Kwality Pharmaceuticals PE ratio and valuation

RatioMar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026Filed 19 May
Revenue growth–43.5%20.7%−16.0%88.6%74.4%−45.0%22.4%20.5%35.9%
Operating profit growth–34.6%––––−64.9%10.5%20.7%47.0%
Net profit growth–36.0%61.4%11.7%82.8%678.8%−83.8%23.2%66.3%68.8%
Earnings per share growth–34.6%61.2%11.8%82.8%678.6%−84.1%25.3%66.3%68.8%
––19.5%19.7%28.1%98.0%10.1%11.2%16.2%22.5%
–––0.1 pts8.5 pts69.8 pts−87.8 pts1.1 pts5.0 pts6.3 pts
From the net margin–––6.4 pts−0.6 pts97.5 pts−69.1 pts0.1 pts4.3 pts3.9 pts
From asset turnover–––−6.7 pts9.6 pts4.4 pts−17.3 pts1.4 pts1.1 pts2.0 pts
From borrowing–––0.4 pts−0.5 pts−32.0 pts−1.5 pts−0.4 pts−0.4 pts0.3 pts
Return on capital employed–––––71.3%15.5%14.5%16.4%21.2%
Cash conversion––––171.0%52.5%216.7%180.7%132.3%25.2%
Interest cover3.34.0–––55.27.54.56.39.0
Debt to equity––0.670.670.560.240.450.430.420.39
Receivable days––86805357107138154204
Inventory days––34943897286187167111
Payable days––––––117106112144
Cash conversion cycle, days––––––276219209171
Working capital days––62994888201196196202
Asset turnover––1.541.151.721.780.720.810.870.96
Assets per rupee of net worth––2.772.822.772.091.821.761.721.75
Sales per rupee of plant––5.893.334.484.432.102.222.593.39
Capital spending to depreciation–––––5.183.201.531.252.25
Plant being built, % of plant in use––––––12.0%0.0%0.0%11.5%
No balance sheet is on record for the years to Mar 2017 and Mar 2018, so its lines and the ratios worked from it are blank there.

Growth and returns over 3, 5 and 10 years

Standalone: the listed company alone, without its subsidiaries. Each window ends with the year to Mar 2026.

Return on assets, latest year
12.9%
Cash from operations against operating profit
14.4%
Measure10 years5 years3 years
Revenue growth, yearly rate–14.0%26.1%
Profit growth, yearly rate–34.3%51.2%
Return on equity, average–31.6%16.6%
Return on capital employed, average–27.8%17.4%
Operating margin, average–25.7%22.3%
Net margin, average9.0%13.2%10.7%
Asset turnover, average–1.030.88
Cash conversion cycle, days, average–219200
Interest cover, average–16.56.6
Debt to equity, average–0.390.42

Where the cash came from and went

Standalone: the listed company alone, without its subsidiaries. ₹ crore, added up over each window, which ends with the year to Mar 2026.

₹ crore5 years3 yearsLatest year
Cash from operations21811317
Cash from investing−201−89−35
Cash from financing−18−257
Capital spending2009745
Dividends paid000
Shares bought back–00
Shares issued for cash000
Borrowings raised834532
Borrowings repaid613814

Accounting checks

Standalone, years to March. Published tests of whether reported profit is backed by cash and the balance sheet.

CheckMar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Receivables growth less revenue growthOur threshold 0 percentage points−5.65−64.07–––––
Inventory growth less cost-of-goods growthOur threshold 0 percentage points126.44−112.71–––––
Other current assets growth less revenue growthOur threshold 5 per cent of revenue8.083.78–––––
Effective tax ratePublished threshold 17.16 per cent24.31––––––
A threshold marked as ours has no published figure; it is the line we read the check against.

Credit ratings

An agency's view of the chance the company repays a borrowing on time, from AAA, the highest, down to D, in default.

DateAgencyBorrowing ratedRatingOutlookAmount, ₹ Cr
7 May 2026ICRA LimitedFund-based/Non-fund based-Others[ICRA]BBB+ /[ICRA]A2Review, UpgradeStable160
7 May 2026ICRA LimitedFund-based-Term loan[ICRA]BBB+Review, UpgradeStable40
5 Dec 2025ICRA LimitedFund-based-Cash creditLong-term scale[ICRA]B+ ISSUER NOT COOPERATINGContinues as Non CoopStable24.08
5 Dec 2025ICRA LimitedNon-fund based-OthersShort-term scale[ICRA]A4 ISSUER NOT COOPERATINGContinues as Non Coop9
5 Dec 2025ICRA LimitedUnallocated limits-Unallocated limitsLong and short-term scales[ICRA]B+ ISSUER NOT COOPERATING/[ICRA]A4 ISSUER NOT COOPERATINGContinues as Non CoopStable9.92
25 Sep 2025CRISIL Ratings LimitedBank FacilitiesLong-term scaleCrisil B(Issuer Not Cooperating)Ratings continues to be INCStable4.12
25 Sep 2025CRISIL Ratings LimitedBank FacilitiesShort-term scaleCrisil A4(Issuer Not Cooperating)Ratings continues to be INC4
25 Sep 2025CRISIL Ratings LimitedBank FacilitiesLong-term scaleCrisil B(Issuer Not Cooperating)Ratings continues to be INCStable6
25 Sep 2025CRISIL Ratings LimitedBank FacilitiesLong-term scaleCrisil B(Issuer Not Cooperating)Ratings continues to be INCStable16
25 Sep 2025CRISIL Ratings LimitedBank FacilitiesLong-term scaleCrisil B(Issuer Not Cooperating)Ratings continues to be INCStable4.88
25 Sep 2025CRISIL Ratings LimitedBank FacilitiesShort-term scaleCrisil A4(Issuer Not Cooperating)Ratings continues to be INC6
25 Sep 2025CRISIL Ratings LimitedBank FacilitiesShort-term scaleCrisil A4(Issuer Not Cooperating)Ratings continues to be INC2
25 Sep 2025CRISIL Ratings LimitedBank FacilitiesLong-term scaleCrisil B(Issuer Not Cooperating)Ratings continues to be INCStable9
The latest rating on each borrowing. The agency's name opens its reasoning for the rating.